Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Advanced Magnetics Announces Retirement of Founder Jerome Goldstein

Abstract:
Advanced Magnetics,Inc. (Nasdaq: AMAG) today announced that Jerome Goldstein, the Executive
Chairman of the Board of Directors and founder of the company, will retire
as an officer and director of the company effective May 1, 2007. The
company's Board of Directors voted to confer on Mark Skaletsky, a member of
the Board of Directors, the role of Chairman of the Board effective as of
Mr. Goldstein's retirement.

Advanced Magnetics Announces Retirement of Founder Jerome Goldstein

CAMBRIDGE, MA | Posted on April 2nd, 2007

Mr. Goldstein founded Advanced Magnetics in November 1981 and completed
its initial public offering in June 1986. Mr. Goldstein commented that "For
25 years, we have developed our iron oxide nanoparticle technology for the
benefit of patients. Two early products, Feridex I.V.(R) and GastroMARK(R),
were brought to market and two additional products, Combidex(R) and
ferumoxytol, both of which I believe could have major beneficial impact,
are in the wings. We have succeeded in putting together an excellent team
capable of accomplishing the company's objectives going forward. I am 68
years old and the time and situation are appropriate for me to pass the
baton on to Brian Pereira. I wish all the employees of Advanced Magnetics
continued success."

Advanced Magnetics' President and Chief Executive Officer, Brian J. G.
Pereira, MD stated, "Jerry's vision and entrepreneurship led to the
founding of Advanced Magnetics and the development of outstanding
diagnostic and therapeutic products with the potential to significantly
improve patients' lives. He has guided the company ably for 25 years and
has been a vital contributor to its success to date, while positioning the
company well for future success. We thank Jerry for his invaluable
contributions over the years and wish him well in his plans for the
future."

####

About Advanced Magnetics
Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products. As a leader in our field, we
are dedicated to the development and commercialization of our proprietary
nanoparticle technology for use in therapeutic iron compounds to treat
anemia, as well as novel imaging agents to aid in the diagnosis of
cardiovascular disease and cancer.

Ferumoxytol, the company's key product candidate, is being developed
for use as an intravenous iron replacement therapeutic for the treatment of
iron deficiency anemia in chronic kidney disease. The company plans to file
a New Drug Application for marketing approval of ferumoxytol with the U.S.
Food and Drug Administration during the fourth calendar quarter of 2007.

Combidex(R), the company's second product under development, is an
investigational functional molecular imaging agent consisting of iron oxide
nanoparticles for use in conjunction with magnetic resonance imaging, or
MRI, to aid in the differentiation of cancerous from normal lymph nodes. In
March 2005, the company received an approvable letter from the FDA with
respect to Combidex, subject to certain conditions.

For more information about us, please visit our website at
http://www.advancedmagnetics.com , the content of which is not part of this
press release.

This document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and federal securities
laws. Any statements contained in this press release that do not describe
historical facts, including but not limited to, statements regarding the
potential beneficial impact of Combidex(R) and ferumoxytol and their
potential for significantly improving patients' lives, the company's
potential accomplishment of its objectives going forward and its potential
future successes, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from
those discussed in such forward-looking statements. Such risks and
uncertainties include the following: (1) the possibility that we may not be
able to successfully complete the development of ferumoxytol, or may not be
able to complete the development in a timely or cost-effective manner, due
to deficiencies in the design or oversight by us of these trials, the
failure of our trials to demonstrate that ferumoxytol is safe and
efficacious, unexpected results from our clinical sites, inadequate
performance by third-party service providers involved in the conduct of the
clinical trials, or any other factor causing an increase in expenses, a
delay and/or a negative effect on the results of the clinical studies for
ferumoxytol; (2) uncertainties surrounding the our ability to obtain
regulatory approval for ferumoxytol from the FDA; (3) the possibility that
the results of past ferumoxytol studies may not be replicated in future
studies; (4) the fact that we have limited sales and marketing expertise;
(5) uncertainties relating to our patents and proprietary rights; and (6)
other risks identified in our Securities and Exchange Commission filings.
We caution readers not to place undue reliance on any forward-looking
statements which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to reflect any
change in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking
statements.

For more information, please click here

Contacts:
Investors:

(617) 498-3361

Media:

(978) 463-7952

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Human Interest/Art

Drawing data in nanometer scale September 30th, 2022

Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022

Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021

JEOL Announces 2020 Microscopy Image Grand Prize Winners January 7th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project